LIDOCAINE HYDROCHLORIDE INJECTION USP 2% LIQUID

Land: Canada

Sprog: engelsk

Kilde: Health Canada

Aktiv bestanddel:

LIDOCAINE HYDROCHLORIDE

Tilgængelig fra:

ALVEDA PHARMACEUTICALS INC

ATC-kode:

N01BB02

INN (International Name):

LIDOCAINE

Dosering:

2%

Lægemiddelform:

LIQUID

Sammensætning:

LIDOCAINE HYDROCHLORIDE 2%

Indgivelsesvej:

BLOCK/INFILTRATION

Enheder i pakken:

20X2/20X5/20X10/10X20/1X50ML

Recept type:

Ethical

Terapeutisk område:

LOCAL ANESTHETICS

Produkt oversigt:

Active ingredient group (AIG) number: 0101280001; AHFS:

Autorisation status:

CANCELLED (UNRETURNED ANNUAL)

Autorisation dato:

2024-01-08

Produktets egenskaber

PRESCRIBING INFORMATION
LIDOCAINE HYDROCHLORIDE INJECTION, USP 1%
LIDOCAINE HYDROCHLORIDE INJECTION USP 2%
2% LIDOCAINE AND EPINEPHRINE 1:100,000 INJECTION USP
Local Anesthetic
Alveda Pharmaceuticals Inc.
40 Holly Street, Suite 801
Toronto, Ontario
M4S 3C3
Submission Control No.: 150278, 152442, 152443
Date of Revision: January 4, 2012
2
TABLE OF CONTENTS
PART I: HEALTH PROFESSIONAL
INFORMATION......................................................... 3
SUMMARY
PRODUCT
INFORMATION................................................................................
3
INDICATIONS
AND
CLINICAL
USE
.....................................................................................
3
CONTRAINDICATIONS
..........................................................................................................
4
WARNINGS
AND
PRECAUTIONS
.........................................................................................
4
ADVERSE
REACTIONS.........................................................................................................
11
DRUG
INTERACTIONS
.........................................................................................................
13
DOSAGE
AND
ADMINISTRATION
.....................................................................................
16
OVERDOSAGE
.......................................................................................................................
20
ACTION
AND
CLINICAL
PHARMACOLOGY....................................................................
21
STORAGE
AND
STABILITY
.................................................................................................
23
SPECIAL
HANDLING
INSTRUCTIONS...............................................................................
23
DOSAGE
FORMS,
COMPOSITION
AND
PACKAGING ..................................................... 24
PART II: SCIENTIFIC INFORMATION
...............................................................................
26
PHARMACEUTICAL
INFORMATION.........................................